CRSP NASDAQ
CRISPR Therapeutics AG
1W: -2.1%
1M: -9.6%
3M: +3.1%
YTD: -8.8%
1Y: -27.1%
3Y: +23.2%
5Y: -49.1%
$51.47
+2.46 (+5.02%)
After Hours: $51.43 (-0.04, -0.08%)
Weekly Expected Move ±6.6%
$43
$46
$49
$53
$56
Credit Risk of going bust: higher than 50% of companies Debt: 14.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.69 (down 99%), CRISPR Therapeutics AG would be worth roughly what it owes.
Total debt $783.7M against a stock market value of $4.74B.
Distance to default 5.09 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $293.1M (short-term plus half of long-term), stock volatility 57.0%; Altman Z'' 3.71. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $783.7M against a stock market value of $4.74B.
Distance to default 5.09 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $293.1M (short-term plus half of long-term), stock volatility 57.0%; Altman Z'' 3.71. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$4M
-90.0% ▼
5Y CAGR: +37.3%
Gross Profit
-$229M
-204.9% ▼
Operating Income
-$568M
-21.8% ▼
Net Income
-$582M
-58.8% ▼
EPS (Diluted)
$-6.47
-49.1% ▼
EBITDA
-$549M
-22.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $913M | $436K | $370M | $35M | $4M |
| YoY Growth | +168054.9% | -100.0% | +85039.0% | -90.6% | -90.0% |
| Cost of Revenue | $101M | $110M | $130M | $110M | $233M |
| Gross Profit | $812M | -$110M | $240M | -$75M | -$229M |
| Gross Margin | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| R&D Expenses | $341M | $462M | $387M | $321M | $265M |
| SG&A Expenses | $100M | $102M | $76M | $73M | $74M |
| Operating Expenses | $438M | $563M | $462M | $391M | $339M |
| Operating Income | $374M | -$673M | -$223M | -$467M | -$568M |
| Operating Margin | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | $380M | -$650M | -$151M | -$363M | -$578M |
| Tax Expense | $2M | -$325K | $3M | $4M | $4M |
| Net Income | $378M | -$650M | -$154M | -$366M | -$582M |
| Net Margin | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |
| EPS (Diluted) | $4.70 | $-8.36 | $-1.94 | $-4.34 | $-6.47 |
| EBITDA | $391M | -$649M | -$203M | -$447M | -$549M |
| Shares Outstanding | 80M | 78M | 79M | 84M | 90M |